**Synopsis**

Transcription factors of the FoxO (forkhead box O) family regulate a wide range of cellular physiological processes, including metabolic adaptation and myogenic differentiation. The transcriptional activity of most FoxO members is inhibitory to myogenic differentiation and overexpression of FoxO1 inhibits the development of oxidative type I fibres in vivo. In this study, we found that FoxO6, the last discovered FoxO family member, is expressed ubiquitously in various tissues but with higher expression levels in oxidative tissues, such as brain and oxidative muscles. Both the expression level and promoter activity of FoxO6 were found to be enhanced by PGC-1α (peroxisome proliferator-activated receptor γ co-activator 1α), thus explained its enriched expression in oxidative tissues. We further demonstrated that FoxO6 represses the expression of PGC-1α via direct binding to an upstream A/T-rich element (AAGATATCAAAACA, –2228–2215) in the PGC-1α promoter. Oxidative low-intensity exercise induced PGC-1α but reduced FoxO6 expression levels in hind leg muscles, and the binding of FoxO6 to PGC-1α promoter was also prevented by exercise. As FoxO6 promoter can be co-activated by PGC-1α and its promoter in turn can be repressed by FoxO6, it suggests that FoxO6 and PGC-1α form a regulatory loop for setting oxidative metabolism level in the skeletal muscle, which can be entrained by exercise.

**Key words:** FoxO6, muscle, oxidative metabolism, PGC-1α, promoter, transcription

Cite this article as: Chung, S.Y., Huang, W.C., Su, C.W., Lee, K.W., Chi, H.S., Lin, C.T., Chen, S.-T., Huang, K.M., Tsai, M.S., Yu, H.P. and Chen, S.L. (2013) FoxO6 and PGC-1α form a regulatory loop in myogenic cells. Biosci. Rep. 33(3), art:e00045.doi:10.1042/BSR20130031

**INTRODUCTION**

The transcription factors of the FoxO (forkhead box O) family, including FoxO1 (FKHR), FoxO3 (FKHR1), FoxO4 (AFX) and FoxO6, have been discovered to play important roles in a diverse cellular physiological functions, including glucose metabolism, stress response, differentiation, cell cycle regulation and apoptosis [1, 2]. Their binding to the cis-response elements (consensus sequence: TTGTTTAC) of target genes is mediated by the forkhead-box DNA-binding domains located at the central region of these factors. In addition to direct binding to DNA, FoxOs can also function as a transcriptional co-regulator of other DNA-binding transcription factors, such as nuclear receptors and HNF4 (hepatocyte nuclear factor 4), through protein–protein interaction [3]. Furthermore, their transcriptional activity is critically regulated by signal transduction pathways-mediated post-translational modification [4]. For instance, insulin-activated PI3k (phosphoinositide 3-kinase)–Akt pathway phosphorylates FoxO1 on T24, S256 and S319 residues and this modification renders FoxO1 to be shuttled out of nucleus [5, 6]. These three Akt-targeted sites, named as T1, S1 and S2, are conserved from Daf16 in Caenorhabditis elegans to its orthologues in mammals [7].

Members of the FoxO family are highly expressed in primary myoblasts. The expression level of FoxO1–4 remains largely unchanged during the terminal myogenic differentiation. However, the levels of their phosphorylation and nuclear localization are

---

**Abbreviations used:** CHIP, chromatin immunoprecipitation; DM, differentiation medium; DMEM, Dulbecco’s modified Eagle’s medium; EMSA, electrophoretic mobility-shift assay; FCS, fetal calf serum; FoxO, forkhead box O; Gapdh, glyceraldehyde-3-phosphate dehydrogenase; GC, gastrocnemius; GM, growth medium; HEK-293T, HEK-293 cells expressing the large T antigen of SV40; HRP, horseradish peroxidase; MBP, maltose-binding protein; MRFs, myogenic regulatory factors; PBST, PBS containing 0.5% Tween 20; PGC-1α, peroxisome proliferator-activated receptor γ co-activator 1α; PI3k, phosphoinositide 3-kinase; qRT-PCR, quantitative reverse transcription PCR; T2D, type 2 diabetes.

1 To whom correspondence should be addressed (email slchen@cc.ncu.edu.tw).
significantly increased in well-differentiated myotubes [8, 9]. These observations are contradictory to what observed in other cell lineages where phosphorylated FoxOs tends to be shuttled out of nucleus, and it suggests that FoxOs might behave differently in myogenic cells. Recent studies have shown that ectopic overexpression of constitutively active FoxO mutants in myoblasts prevents/retards myogenic differentiation or induces atrophy [9–11]. Transgenic mice overexpressing FoxO1 show reduced muscle mass, down-regulated type I fibre genes and impaired glycemic control [12]. It has been demonstrated that FoxOs induce muscular atrophy through activating the transcription of muscle-specific ubiquitin ligases Atrogin-1 and MuRF1 as well as a novel ubiquitin-binding protein called as ZNF216 [10, 11, 13]. Unfortunately, the direct targets of FoxOs in the genetic axis of myogenesis have not yet been identified to date.

The last discovered member, FoxO6, of this family was identified by screening novel forkhead transcription factors expressed in the ventral midbrain [14]. Its high expression in the central nervous system and dorsal root ganglion was later confirmed [15]. Outside the nervous system, it is also expressed in the thymus, cortex of kidney and limb buds [14]. Its expression in the somites or having any role in trunk muscle development has not been reported yet. One distinguishing character of FoxO6 is its constant/high nuclear localization upon growth factors stimulation due to lacking of a phosphorylation motif (S316) conserved in other FoxOs. Nevertheless, its transcriptional activity is regulated by phosphorylation sites, but which is independent of nucleocytoplasmic shuttling [16].

FoxOs have been reported to regulate oxidative metabolism by directly activating the expression of PGC-1α (peroxisome-proliferation-activated receptor γ co-activator 1α) [17], which is a versatile transcriptional co-activator playing critical roles in the biogenesis of mitochondria, gluconeogenesis and fatty acid oxidation [18, 19]. In muscle, PGC-1α is preferentially expressed in slow-twitch fibres and its enhanced expression can convert fast-twitch fibres into slow-twitch fibres in vivo [20]. The activation of slow-twitch muscle-specific genes by PGC-1α is mediated through the binding of Mef2 transcription factors on their upstream enhancer sites. Mef2 proteins also activate the transcription of PGC-1α gene and thus establish a positive feedback loop [21].

In this study, we examined the expression pattern of FoxO6 in various tissues and during myogenic differentiation at both mRNA and protein levels. We found that FoxO6 is expressed ubiquitously but with higher expression levels in oxidative tissues, such as brain and oxidative muscles. During myogenesis, FoxO6 expression is only activated in differentiated myotubes regardless of fibre types. We further demonstrated that FoxO6 represses the expression of PGC-1α via direct binding to an upstream A/T-rich element (AAGATATCAAAAAC, −2286 to −2273) and this repression can be released by exercise. Co-activation of FoxO6 promoter by PGC-1α was also observed, which indicates that FoxO6 and PGC-1 form a regulatory loop for oxidative metabolism. This study has identified the second FoxO6 target gene outside the nervous system and suggests the possible implication of FoxO6 in regulating oxidative metabolism by repressing PGC-1α expression.

**MATERIALS AND METHODS**

**Plasmids**

The reporter construct containing the full length (−3170 to +101) PGC-1α promoter has been described before [22], but with the numbering system changed to the latest identified transcription initiation site (accession no.: NC_000071.6/GI:372099105). The deletion mutants of this promoter were constructed by digesting the full-length clone with either EcoRV or PstI in conjunction with KpnI to create reporters containing −2222 to +101 and −762 to +22 regions of this promoter. Reporters containing other regions of the PGC-1α promoter were created by inserting pfu DNA polymerase-amplified PCR products into the Smal site of pGL2-tk-enhancer vector (Promega). All PCR products were sequenced to confirm their sequence integrity. The expression vector pMCSV–FoxO6 was created by inserting FoxO6 coding sequence released from pEGFP–FoxO6 vector (a generous gift from Dr Marten P. Smidt; Department of Pharmacology and Anatomy, University Medical Center, Utrecht) with SalI/BamHI (blunt) into the Xhol site of pMCSV vector. pCDNA3–FoxO6–MCS was created by inserting FoxO6 CDS released from pEGFP–FoxO6 vector with HindIII/XhoI site of pCDNA3 vector to generate a chimaeric gene containing FoxO6 CDS and the multiple cloning sites (BamHI to XbaI, 78 bp) of the vector. Similarly, FoxO6 CDS was amplified with primers containing Flag-tag and inserted into the Xhol site of the pP3/CAG-IP vector to create C-terminal Flag-tagged FoxO6 expression vector that allows stable selection with puromycin. The CDS (559 amino acids) of FoxO6 was also amplified from C2C12 cDNA and cloned into the EcoRV site of pCDNA3 vector to generate pCDNA3–FoxO6. The least conserved region (mRNA + 685 to +1476, amino acid 229–492) of FoxO6 was inserted into the BamHI/EcoRI sites of modified pET-32a vector, in which the 3′-His-tag was made in-frame by blunting the NotI/XhoI sites, to generate FoxO6 (229–492) protein with His-tag on both ends. FoxO6 promoter (−2977 to +299) was amplified from mouse genomic DNA by PCR and inserted into the HindIII and XhoI sites of the pGL3-basic vector.

**Cell culture and transient promoter assay**

Proliferating C2C12 myoblasts were kept in GM (growth medium) containing DMEM (Dulbecco’s modified Eagle’s medium) supplemented with 20% (v/v) FCS (fetal calf serum). Myogenic differentiation was induced by replacing the medium with DM (differentiation medium) containing DMEM supplemented with 2% (v/v) horse serum. For transient transfection, PGC-1α promoter-driven reporter vector (0.67 μg) and pMCSV–FoxO6 (0.33 μg) were mixed together in 1× Hepes buffer (20 mM Hepes at pH 7.0, 187 mM NaCl, 5 mM KCl, 0.7 mM Na2HPO4 and...
5.5 mM dextrose) in 1.5 ml test tubes and then liposome (Lipofectamine, Invitrogen) in 1 × Hepes buffer were added to the DNA mixture and incubated at room temperature (25 °C) for 10–15 min to allow DNA and liposome complex to form. Aliquots (1 ml) of culture medium were added to each tube and mixed with several inverting. Medium containing the DNA/liposome complex in each tube was transferred to cells grown in a 12-well Petri dish and the transfection was allowed to proceed overnight before the medium was replaced by fresh DM containing either 2% (v/v) horse serum or GM containing 20% (v/v) FCS. Cells were harvested and assayed for luciferase activity 48 h after transfection in a Clarity 2 luminometer (BioTEK; Winooski, VM). All experiments were performed in triplicates and repeated at least three times.

Stable cloning of FoxO6 overexpressed C2C12 myoblasts

The stable cloning of C2C12 myoblasts has been described before [23]. Briefly, C2C12 grown on a single well of a 6-well Petri dish were transfected with pPyCAG-IP–FoxO6 for overnight and plated into a 10 cm dish and started selection with puromycin (3 μg/ml). Medium containing the DNA/liposome complex to form. Aliquots (1 ml) of culture medium were added to each tube and mixed with several inverting. Medium containing the DNA/liposome complex in each tube was transferred to cells grown in a 12-well Petri dish and the transfection was allowed to proceed overnight before the medium was replaced by fresh DM containing either 2% (v/v) horse serum or GM containing 20% (v/v) FCS. Cells were harvested and assayed for luciferase activity 48 h after transfection in a Clarity 2 luminometer (BioTEK; Winooski, VM). All experiments were performed in triplicates and repeated at least three times.

qRT-PCR (quantitative reverse transcription PCR)

The protocol for qRT-PCR has been described previously [24]. Briefly, total RNA was extracted from C2C12 cells using TRI- ZOLE kit, then, the first strand of cDNA was synthesized using the Superscript III kit according to the supplier’s instruction. Quantitative real-time PCR was performed in a 20 μl reaction mixture containing 5 μM forward/reverse primers, 1 × SYBR Green reaction mix (Applied Biosystems) and various amounts (equivalent to about 25, 50 and 100 ng of the total RNA) of templates. A tube containing equivalent amount of total RNA was used as reverse transcriptase control and amplified in the same PCR reaction. Only samples shown free of genomic contamination were further analysed. Gapdh (glyceraldehydes-3-phosphate dehydrogenase) was used as internal control amplified in the same PCR assay. The primer sets used were listed in Table 1. All reactions were performed in an ABI 7300 sequence detection system.

EMS (Electrophoretic mobility-shift assay)

The detailed protocol of EMSA has been described previously [22, 25]. Briefly, 32P-labelled oligonucleotide corresponding to the putative FoxO6-targeted site (region) in PGC-1α promoter was made by polynucleotide kinase (PNK, New England Bio-labs) mediated end-labelling reaction in the presence of 50 μCi γ-32P-ATP. 32P-labelled probe was further purified by adsorbing onto DAE cellulose filter paper (DE-81,Whatman) and eluted out with Tris buffer containing 1 M LiCl after extensive wash in 70% ethanol. Bacteria expressed proteins (0.5 μg) were used to bind 32P-labeled oligonucleotide probe in 25 μl binding buffer (25 mM Hepes at pH 7.4, 5 mM MgCl2, 4 mM EDTA, 2 mM DTT, 110 mM NaCl, 5 μg/ml BSA and 0.8% Ficol) at room temperature for 30 min. Protein and DNA complexes were resolved on a 5% (w/v) acrylamide low ionic gel containing 5% (v/v) glycerol at 4 °C for at least 3.5 h. Signals on the gels were viewed by autoradiography.

DNase I footprinting assay

Taq DNA polymerase amplified PGC-1α promoter fragment –2310 to –1902 was cloned into the T-tailed EcoRV site of yT&A vector to make the yT&A (–2310 to –1902)-construct. For labelling the 5’ end of this fragment, this construct was first digested with EcoRI and then labelled with Klenow reaction in the presence of 50 μCi α-32P-ATP. The labelling on the upstream vector end was removed by digestion with KpnI and the probe was further purified with DNA purification spin columns (DF300, Geneaid Biotech). Probe (8 × 105 cpm) and various amounts (0.25 and 0.5 μg) of MBP (maltose-binding protein) or MBP–FoxO6

| Table 1: The sequences and amplicon sizes of the primer sets used in this study |
|---|---|---|---|---|
| Gene | Amplicon size (bp) | Forward primer | Reverse primer | Purpose |
| Gapdh | 190 | 5′-CCTGTGGAAGCTGTGGGCTG-3′ | 5′-TTGCCAGGTTCCTCCAGGCG-3′ | qRT-PCR |
| PGC-1α | 166 | 5′-GAGGCGCTGCTGAT1TTACG-3′ | 5′-GGCGAAACGGTCACAGGT-3′ | qRT-PCR |
| FoxO6 | 172 | 5′-CTACAGCTCTGCGAGAGCTA-3′ | 5′-GACCTCCACGAGACCTGC-3′ | qRT-PCR |
| PGC-1α | 252 | 5′-TTCGCCCTCAACTTCTCATACCA-3′ | 5′-TATGACAGTGATCCGGAGAGATC-3′ | CHIP assay (−99817 to −99566) |
| PGC-1α | 400 | 5′-GCTCTAGAGTAGTGGTGGG-3′ | 5′-AGTGTGCTGGCTCTACTTC-3′ | CHIP assay (−2390 to −1990) |
| FoxO6 | 243 | 5′-GCAGAGGGCGCTGCTGGAGTG-3′ | 5′-ATCCAGTCCCTGTAAGCAGC-3′ | CHIP assay (−103 to +141) |
| PGC-1α | 3251 | 5′-GTCCCTGCACTGGCTTAT-3′ | 5′-CAATCCACTCTGACACACA-3′ | Promoter cloning (−3170 to +101) |
| FoxO6 | 3276 | 5′-CCAGGGAGGATAGAAGATAT-3′ | 5′-GATGGGTGCGGCCAGAAG-3′ | Promoter cloning (−2977 to +299) |
| FoxO6 | 792 | 5′-CAAGCTTGGATGGCGCGCCA-3′ | 5′-GGATCCCCGCGCGCTGGCG-3′ | Cloning of FoxO6 (229-492)-His |

© 2013 The Author(s) This is an Open Access article distributed under the terms of the Creative Commons Attribution Licence (CC-BY) (http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.

487
were incubated in buffer A (10 mM Tris, pH 8.0, 5 mM MgCl2, 1 mM CaCl2, 2 mM dithiothreitol, 50 μg BSA/ml, and 2 μg/ml salmon sperm DNA) at 37 °C for 30 min before addition of DNase I (0.01 units) and incubated for another 2 min at room temperature. The reaction was stopped by adding 700 μl Stop solution (645 μl ethanol and 55 μl saturated ammonium acetate) and the mixture was left at −20 °C for 30 min to precipitate the DNA. After washing with 75 % (v/v) ethanol 1–2 times, the residual ethanol was removed by air-dry. DNA was reconstituted in 6 μl gel-loading solution and left at 75 °C for 3 min to increase the solubility. Then, samples were spun at 10000 rpm to collect the solution before loading into 6 % (w/v) acrylamide sequencing gel buffered with 0.5 × TBE. Sequencing gels were run at 1800 V for 2–3 h until the front dye reached the bottom of the gels and the signals on the gels were viewed with autoradiography.

Polyclonal antibody generation and Western blot
PET32a vector carrying FoxO6 coding region corresponding to amino acid 229–492 was transformed into BL-21 strain Escherichia coli cells and induced by IPTG (isopropyl β-D-thiogalactoside) to express His-tagged FoxO6 (229–492 protein). Recombinant protein was purified by nickel column (Chelating Sepharose, GE healthcare) and aliquots (100–200 μg) of purified protein were mixed with Freund’s adjuvant before injected subcutaneously into the dorsal flank of rabbits every other weeks for 2 months. Blood was collected by cardiac puncture and allowed to coagulate for at least 3 h before centrifuged at 3000 rpm for 30 min for collecting anti-serum. The animal experiments were performed in accordance with the guidelines of the Experimental Animal Care and Use Committee of the National Central University.

The protocol for Western Blot has been described previously [23]. Briefly, aliquots of total lysate (50 μg) in RIPA buffer (20 mM TRIS, 150 mM NaCl, 1 % (w/v) deoxycholate, 0.1 % (w/v) SDS, 1 % (v/v) Triton X-100, pH 7.8) supplemented with protease inhibitors were run on SDS/PAGE (10 % gel) before blotted onto a PVDF membrane (Pall FluoroTrans W membrane, Pharmacia Biotech) and visualized on X-ray films (Super RX, Fuji Medical X-film; Tokyo, Japan). The signals were detected by a chemiluminescence kit (Amerham Pharmacia Biotech) and visualized on X-ray films (Super RX, Fuji Medical X-film; Tokyo, Japan). For detection of Gapdh as internal control, all the blots were stripped, washed, and then incubated with Gapdh antibody (diluted 1:500; Sc-815, Santa Cruz) and HRP conjugated secondary antibody described as above. The antibodies for FoxO1 and PGC-1α were purchased from Cell Signaling (no. 28805) and ABCam (no. ab72230), respectively.

Oxidative low-intensity exercise and CHIP (chromatin immunoprecipitation) assay
Male mice of 4–6 months old were mounted to a home-made running wheel (circumference: 70 cm) rotating at 7.5 circles/min and the running was allowed to last for an hour (total running length: 315 m). This oxidative low-intensity running was repeated once per day for consecutive 7 days. At the end of last running, mice were sacrificed 2–3 h after exercise when the expression of PGC-1α is at its peak level and to avoid the immediate acute effect of the exercise [26]. All animal experiments were performed in accordance with the guidelines of the Experimental Animal Care and Use Committee of the National Central University.

The detailed protocol of CHIP assay has been described before [27]. Briefly, GC (gastrocnemius) and soleus muscles were isolated, quickly minced in cold PBS, and fixed in formaldehyde (1 %, v/v) for 20 min. Then, tissues were washed and quenched with cold PBS containing 125 mM glycerol before resuspended in lysis buffer (50 mM Tris/HCl, 150 mM NaCl, pH 8.1, 0.1 % (w/v) SDS, 1 % (v/v) Triton X-100) and sonicated with at least five times of 30 s 140–150 W pulse. The lysate was cleared by spinning and then protein A/G agarose (80 μl) was added to the supernatant and incubated at 4 °C for 1 h before spun at 4000 rev./min for 5–10 min at 4 °C to clear the solution. The supernatant was transferred to a new tube and 1 μg specific antibody was added. The binding was allowed to proceed at 4 °C overnight. Protein A/G agarose (80 μl) was added and incubated for another hour to capture the immune complex. The beads were collected and washed four times in lysis buffer for 10 min; then, washed once in LiCl buffer and twice in 1 × TE for 5 min. The immune complex was eluted twice with 250 μl of elution buffer and the eluate was heated at 65 °C for at least 6 h to reverse the cross-linking. DNA was extracted with phenol/chloroform twice and further purified using a PCR purification Kit (Geneaid; Taipei, Taiwan) before amplified with primers targeting PGC-1α promoters. PCR of a PGC-1α upstream site (∼ 99857 to ∼ 99642) served as a negative control. The relative amount of co-immunoprecipitated DNA was determined by PCR and compared with that of input DNA.

RESULTS
FoxO6 is ubiquitously expressed but enriched in oxidative tissues
To explore the function of FoxO6 in the adult tissues, we firstly examined the expression of FoxO6 mRNA in various tissues of adult mice by qRT-PCR. Similar to previous studies [14, 28], we found that FoxO6 is highly expressed in the brain tissues, with the highest level in the pituitary, implying that FoxO6 might be involved in the regulation of endocrine system. The expression of FoxO6 in the heart, liver and kidney is rather low; on the contrary, substantial amount of it was expressed in the skeletal muscles, especially higher in the oxidative type I soleus muscle, suggesting that FoxO6 expression is preferentially enriched in tissues relying on oxidative metabolism as their major energy source.
**Figure 1** Detecting the expression of FoxO6 at both mRNA and protein levels in various tissues  

(A) The expression of FoxO6 mRNA in various mouse tissues (N = 3) was determined by qRT-PCR. The expression level of FoxO6 in liver was arbitrarily set as 1-fold and compared by the levels in other tissues. ***, P < 0.01 as compared with that of liver.**  

(B) In vitro translated 35S-FoxO6 was detected with either autoradiography (lower panel) or Western blot (upper panel) using home-made polyclonal antibody. FoxO6-MCS is a chimera protein containing FoxO6 CDS and the multiple cloning sites (from BamHI to XbaI) of pCDNA3 vector. Lysate: reticulocyte total lysate used for translation. *, non-specific band caused by haemoglobin in the reticulocyte.  

(C) GFP fused FoxOs were expressed in HEK-293 cells and their expression were detected by GFP antibody (lower panel) or FoxO6 antibody (upper panel). Total lysate (50 μg) from mouse and primate cells (D) or various mouse tissues (F and G) were examined for their expression of FoxO6 by Western blot. The signals of Gapdh serve as input control.  

(E) Alignment of FoxO6 cDNA sequences (1603–1622) reported by IMAGE Consortium, Smidt’s group, and our group (C2C12). The corresponding genomic sequence is also aligned. Numbering is according to Smidt’s clone. GC, gastrocnemius; EDL, extensor digitorum longus; TA, tibialis anterior; Quad, quadriceps.  

As the study of FoxO6 had been hindered by the lack of commercially available FoxO6-specific antibody, we set out to generate FoxO6-specific antibody by injecting recombinant FoxO6 protein fragment (Supplementary Figure S1, available at http://www.bioscirep.org/bsr033/bsr033e045add.htm) corresponding to the least conserved domain (amino acid 229–492, Supplementary Figure S2, available at http://www.bioscirep.org/bsr033/bsr033e045add.htm) among FoxOs into rabbit to induce polyclonal antibody. This polyclonal antibody recognizes in vitro translated FoxO6 protein and GFP–FoxO6 transiently expressed in HEK-293T (HEK-293 cells expressing the large T-antigen of SV40) cells without cross-reacting with other FoxOs (Figures 1B
Surprisingly, high level of FoxO6 protein was observed in the heart and kidney where low level of FoxO6 mRNA was detected, implying that in these tissues either the translation efficiency or the protein stability of FoxO6 was highly increased by unknown mechanisms. As the expression pattern of FoxO6 protein correlates well with that of PGC-1α, it suggests that the expression of FoxO6 might be targeted by PGC-1α, a master regulator of oxidative metabolism.

**PGC-1α enhances FoxO6 expression**

The regulation of FoxO6 by PGC-1α was examined by over-expressing PGC-1α in HEK-293T cells, which allowed super-transfection of pPyCAG-IP-PGC-1α vector due to large T antigen driven replication of this vector. Using qRT-PCR, we found that FoxO6 mRNA level was significantly increased by PGC-1α over-expression (Figures 2A and 2B), suggesting that FoxO6 is a *bona fide* target of PGC-1α. It was of interest to know whether PGC-1α directly co-activated the promoter activity of FoxO6. To address this issue, we cloned the promoter of FoxO6 and co-transfected it with PGC-1α in C2C12 cells induced to differentiate. We found that FoxO6 promoter activity was significantly enhanced by PGC-1α in differentiated myotubes, demonstrating that PGC-1α directly targets FoxO6 promoter and promotes its expression in oxidative tissues.

**FoxO6 represses PGC-1α expression in myogenic cells**

It has been shown that FoxO1 activate PGC-1α expression in hepatocyte to enhance gluconeogenesis [17], but in muscle it down-regulates type I fibre and oxidative genes [12], suggesting...
that FoxOs may regulate PGC-1α in a tissue-specific manner. Whether the same relationship exists between FoxO6 and PGC-1α needs to be examined. We found that overexpression of FoxO6, suppressed PGC-1α expression in confluent myoblasts kept in GM (Figure 3B), indicating that FoxO6 is a repressor of PGC-1α expression in skeletal muscle.

It is of interest to know whether FoxO6 directly regulates the expression of PGC-1α in muscle cells. To address this issue, PGC-1α promoter (−3170 to +101) was co-transfected with FoxO6 into C2C12 cells to reveal if it is targeted by FoxO6. As in the stable clones, FoxO6 repressed PGC-1α promoter activity regardless of the differentiation condition (Figure 3C), suggesting that FoxO6 directly targets PGC-1α promoter.

FoxO6 targets an upstream region in PGC-1α promoter

To further define the mechanism by which FoxO6 regulate PGC-1α promoter, we set out to make series of 5′-end deletion mutants of PGC-1α promoter to identify the response elements targeted by FoxO6. Deletion of the region −3170 to −2224 had no effect on the FoxO6-mediated repression (Figures 3A and 3B). However, further deletion to −763 abolished the repression (Figures 3A and 3B), implying that the region −2223 to −763 contains FoxO6-targeted sites, and this speculation was confirmed by the strong repression of the region −2252 to −710 by FoxO6. Further dissection of this region showed that the significant repression was still preserved within the region −2252 to −1843; indicating that this region harbours major FoxO6 target sites. Therefore this region was further dissected into four fragments and examined for their repression by FoxO6. Among these four fragments, only the activity of the fragment −2252 to −2156 was repressed by FoxO6 (Figures 3C and 3D), as a result, we focused our further study on this region.

FoxO6 directly binds to an upstream A/T-rich element in the PGC-1α promoter

Although FoxO6 can repress the activity of the region −2252 to −2156, it does not necessarily mean that FoxO6 binds directly to this region. Apart from the direct binding, FoxO6 can also repress PGC-1α transcription either by blocking the activity of other DNA-binding transcription factors through protein–protein interaction or by regulating the expression of other upstream
transcription factors. To further define the mechanisms by which FoxO6 repressed PGC-1α promoter activity, we examined the direct binding of FoxO6 to PGC-1α promoter DNA with electrophoresis gel mobility shift assay (EMSA). The binding of MBP–FoxO6 to the four fragments spanning the region −2252 to −1843 was examined and specific binding was only found to fragment −2252 to −2155 (Figure 4A), confirming the results observed in the transfection assay (Figures 3C and 3D). Deletion of the region −2185 to −2155 had no effect on the binding (Figure 4B, lanes 4–6), but deletion of the region −2252 to −2212 abrogated the binding (Figure 4B, lanes 7–9). Therefore the binding sites of FoxO6 should localize in the region −2252 to −2186. Since the consensus sequence: (TTGTATAC) of the FoxO-binding sites was a short A/T rich element, we examined whether a similar sequence existing within the region −2252 to −2186. As expected, an A/T rich region (−2228 to −2211) was found in the middle of this region. To further verify if FoxO6 did bind to this A/T-rich region, a DNase I footprinting assay was performed and we found that FoxO6 specifically protected the region −2228 to −2215, especially on nucleotides A in this region (Figure 5C). Enhanced digestion of two neighbouring regions (−2238 and −2212 to −2209) was also observed upon FoxO6 binding, implying that this binding had induced dramatic conformational change in the DNA. The binding of FoxO6 to this region in vivo was confirmed using CHIP assay, in which we found that FoxO6 specifically targeted this region without binding to the proximal promoter region (Figure 5D). These observations suggest that FoxO6 directly binds to the A/T-rich element (AAGAGATACAAAAC, −2228 to −2215) to repress PGC-1α transcription. It will be interesting to know how FoxO6 and other factors binding to this distal upstream cis-element communicate with polymerase II machinery to compromise its transcriptional activation.

**Oxidative low-intensity exercise relieves FoxO6 mediated repression of PGC-1α**

The enriched expression level in oxidative muscle and direct repression of PGC-1α expression presents a conundrum for FoxO6 in metabolic regulation. To better understand its role in oxidative metabolism regulation, the effect of oxidative exercise on the expression of PGC-1α and Foxo6 was examined. PGC-1α expression was highly induced upon exercise in both GC and soleus muscles (Figure 6A). However, the expression of FoxO6 was repressed by oxidative exercise in both muscles, suggesting that FoxO6-mediated PGC-1α repression can be relieved by exercise (Figure 6A). To confirm this speculation, we examined the binding of FoxO6 to PGC-1α promoter in vivo by CHIP assay. As expected, FoxO6 bound to PGC-1α promoter strongly in sedentary muscles but was released from the promoter in exercised muscles (Figure 6B) to allow the activation of PGC-1α promoter in exercised muscles.

**DISCUSSION**

**Sequence comparison of FoxO6-binding sites**

Although FoxO6 has been identified for a few years, very few target genes have been identified until recent years, partially due
to its unique distribution and lack of available antibody. It is conceivable that FoxO6 should play critical roles in the development of nervous system due to its enriched expression in the central nervous system. A FoxO–Pak1 transcriptional loop has now been identified to regulate neuronal polarity during early embryogenesis [29]. Reduced expression of FoxO6 and other members of the family in the cerebellar granule neurons abrogate their axo-dendritic polarity. This polarity can be rescued by overexpression of Pak1, demonstrating its role downstream of FoxO6. Direct targeting of FoxO6 on the Pak1 promoter to activate its expression in the neurons to regulate their axo-dendritic polarity is also demonstrated. The FoxO6-binding site (TGTTTAAACG) is located in the −1223 to −1212 region of the rat Pak1 promoter and complies with the rules of A/T rich and distal to the transcriptional initiation site. Like other FoxOs, FoxO6 has been implicated in the hepatic gluconeogenesis upon fasting by...

Figure 5  FoxO6 directly binds to an upstream A/T-rich element in the PGC-1α promoter

(A and B) Bacteria expressed MBP or MBP-FoxO6 (0.5 μg) was used to bind 32P-labelled DNA probes spanning the region −2252 to −1843 in EMSA. Cold probe and Gapdh DNA (×100) were included in the reaction to test the binding specificity of MBP-FoxO6 to each probe. (C) DNase I footprinting of MBP-FoxO6-binding sites in PGC-1α promoter. 32P-labelled DNA probes (−2252 to 1843) was digested with DNAse I in the presence and absence of MBP or MBP-FoxO6 proteins before resolved on a 6 % sequencing gel. The signals on the gel were viewed by autoradiography. The corresponding position of each base in the probe is shown to the left. The images of both short (16 h, left panel) and long (48 h, right panel) exposures of a representative gel are shown here. (D) CHIP assay using antibodies against FoxO6 or non-specific IgG. Precipitated chromatin was amplified by primer sets targeting different regions of the PGC-1α promoter. The priming sites are shown on the top panel. NTC, no template control for PCR. The upstream priming sites (−99875 to −99642) were used as a negative control of CHIP assay.
activating the expression of gluconeogenic enzymes, such as PPECK and G6Pase, and which can be blunted by insulin [28]. The insulin response element in the G6Pase gene promoter consists of 3 T/A-rich heptamers, but whether they are directly bound by FoxO6 remains to be demonstrated.

The FoxO6-protected site (AAGATATCAAAACA, −2228 to −2215) in the PGC-1α promoter complies with the same A/T-rich rule and is the third FoxO6 target site identified to date. Since the FoxO6 target site in the Pak1 promoter is also bound by other FoxOs, it will be interesting to know whether the same scenario happens to that in the PGC-1α promoter. Alignment of the PGC-1α promoter sequences from several mammals (Figure 7A) shows that the FoxO6-binding site in PGC-1α promoter is only marginally conserved (43% identity). However, some of the A/T bases are 100% conserved among mammals, suggesting their importance in the transcriptional regulation of PGC-1α gene by FoxO6. The divergence of other bases may reflect differential regulation of PGC-1α during evolution of mammals.

Although FoxO6 protected the region −2228 to −2215, we also found that the promoter region −2223 to +101 could be well repressed by FoxO6 (Figures 4A and 4B), suggesting that the region −2223 to −2215 (ATCAAAACA) can serve as a minimal FoxO6 response element. We are currently demonstrating that whether this element can confer target promoters negative regulation by FoxO6.

PGC-1α and FoxO6 form a regulatory loop for oxidative metabolism

Multiple pathways have been found to activate PGC-1α expression, including Mef2-dependent auto-regulation [30], β-adrenergic signalling pathway mediated muscle contraction nerve signals [31, 32] and hormones, such as thyroid hormone or inhibiting, such as insulin, activating oxidative metabolism [17, 33, 34]. Insulin represses PGC-1α expression in hepatocyte and its signal is mediated by the PI3K–Akt pathway to phosphorylate members of the FoxO family of transcription factors. Phosphorylated FoxOs are shuttled out of the nucleus, so that they cannot bind to the IRES (insulin response elements) on the PGC-1α promoter to activate its expression [17]. In muscle, we previously have found that MRFs (myogenic regulatory factors), especially MyoD and Myogenin, can strongly activate PGC-1α expression [35]. As both MRFs and Mef2 are essential for muscle formation/differentiation and they are abundant in differentiating

Figure 6 Exercise releases FoxO6-mediated PGC-1α repression

(A) The expression levels of PGC-1α and FoxO6 in hind leg muscles of sedentary and exercised mice (N = 3) were determined with qRT-PCR. The expression level of each gene in the sedentary mice was arbitrarily set as 100%. * and **, P < 0.05 and P < 0.01, respectively, as compared with that of the same muscle in sedentary mouse. (B) Binding of FoxO6 to PGC-1α promoter in hind leg muscles was examined with CHIP assay as described in Figure 5.

Figure 7 FoxO6-targeted site in the PGC-1α promoter is conserved among mammals

PGC-1α promoters from various mammals were aligned and compared with Vector NTI software and the alignment of the region corresponding to the FoxO6-targeted site in mouse PGC-1α is summarized here. Numbering on the top represents the location in mouse PGC-1α promoter relative to the major transcription initiation site. The putative minimal FoxO6 response element (−2223 to −2215) is indicated at the bottom.
myotubes, it will be interesting to know how these transcription factors communicate with FoxO6 on the PGC-1α promoter to determine its expression level and the oxidative metabolism status of muscles in resting and exercising subjects.

The relief of FoxO6-mediated PGC-1α repression by oxidative low-intensity exercise has opened a new window for understanding the balance of oxidative and glycolytic metabolism in muscle. The higher expression level in oxidative muscle and its repressive effect on PGC-1α promoter activity has puzzled us until we found that exercise can release the repression, especially in soleus muscle. These observations suggest PGC-1α and FoxO6 form a regulatory loop to maintain the expression level of each other and this balance can be tipped by factors or messengers, such as Mef2 and Ca^{2+}, mediating signalling pathway of exercise [36] to determine the final level of oxidative respiration in the cells (Figure 8). The higher FoxO6 levels in oxidative tissues may reflect its transcriptional activation by PGC-1α before the amount of FoxO6 is high enough to repress PGC-1α expression, implying that PGC-1α promoter may have lower sensitivity to FoxO6 repression, so it can achieve higher PGC-1α levels in oxidative tissues, which also allows higher level of FoxO6 to accumulate. It will be interesting to know how intracellular exercise signalling pathways relieve the repression of PGC-1α by FoxO6 and whether these mechanisms can reset the sensitivity of PGC-1α promoter to FoxO6-mediated repression.

Although FoxO1 has been found to activate PGC-1α expression in hepatocytes [17], the same regulation has not been observed in skeletal muscle. On the contrary, we found that both FoxO1 and FoxO6 actively repress PGC-1α promoter activity in myoblast cells (Figure 3 and results not shown), this functional discrepancy of FoxOs in these two organs might reflect different roles of these two organs in metabolism: as liver is a source and muscle is a sink of glucose. Both FoxO1 and FoxO6 have been found to increase gluconeogenesis in liver to increase blood glucose level during fast [28]. However, overexpression of FoxOs in muscle reduces type I fibres [12] and induces atrophy by activating the expression of muscle-specific ubiquitin E3 ligases Atrogin-1 and MuRF-1 [37, 38]. Furthermore, this atrophic effect can be rescued by PGC-1α overexpression. Therefore these data suggest that FoxOs and PGC-1α antagonize each other’s activity to maintain the homeostasis of metabolism in muscle. As overexpression of PGC-1α strongly promotes oxidative respiration and inhibits catabolism, compromising of its activity is important for the normal muscular composition, in which both fast and slow fibre are required and proper fibre type composition and muscle/fibre size are arranged to meet the demand of either fast or slow movements. Therefore the antagonism of PGC-1α promoter activity by FoxO6 and its relief under certain physiological condition represents a novel mechanism regulating normal muscle metabolism and fibre type composition.

**Repression of PGC-1α by FoxO6 may be involved in the pathogenesis of degenerated diseases**

In obesity and T2D (type 2 diabetes) patients, their skeletal muscle shows a phenotype characteristic of reduced oxidative enzyme activity, increased glycolytic activity and increased lipid content. Reduced PGC-1α expression is observed in some subjects of both diseases [39, 40], demonstrating its importance in muscular metabolism. The key glucose transporter, Glut4, on the plasma membrane is also reduced in T2D patients and the expression of Glut4 in cultured skeletal muscle cells can be restored by PGC-1α overexpression through a Mef2-dependent pathway [41]. Therefore restoring the expression of PGC-1α normal level seems to be a priority in the management of these diseases. Recent studies have shown that PGC-1α can suppress ROS (reactive oxygen species) and neurodegeneration [42]; furthermore, its expression in degenerated neuron diseases, such as Alzheimer disease, is significantly reduced [43, 44]. Considering the importance of preventing the initiation of these degenerated diseases, it is of interest to know whether the reduced expression of PGC-1α in these subjects affected by DM or degenerated neural diseases is caused by the repressive activity of FoxO6 as discovered in this study. This notion has been supported by the observation that reduction of FoxO6 expression level by infusion of shRNA (small-hairpin RNA)-expressing virus shows
Significant beneficial effect on db/db mice [28]. Therefore, it is important to characterize the expression pattern of PGC-1α and FoxO6 in these diseased subjects and reveal their correlation with the progress of the diseases.

**AUTHOR CONTRIBUTION**

Shih Ying Chung characterized the expression pattern of FoxO6 and PGC-1α, examined their binding to target promoters in vivo and demonstrated the activation of FoxO6 expression by PGC-1α. Wei Chieh Huang discovered the negative regulation of PGC-1α by FoxO6 and did the initial promoter assays. Ching Wen Su characterized the expression pattern of FoxO6 mRNA and she also expressed FoxO6 protein and induced antibody in rabbits. Kuan Wei Lee performed the promoter assay and identified the FoxO6-targeted region by EMSA. Hsiang Cheng Chi initiated the FoxO study and interpreted the clinical significance of results. Kai Min Huang cloned the FoxO6 gene, examined their binding to target promoters and demonstrated the activation of FoxO6 and PGC-1α by FoxO6 and did the initial promoter assays. Ching Tao Lin performed the footprinting assay. Shu-Tah Chen supported this study and interpreted the clinical significance of results. Kam Min Huang cloned the PGC-1α promoter. Mu Shiun Tsai helped with the immunofluorescence assays on cells and tissue sections. Hui Peng Yu isolated protein from various tissues and did the immunofluorescence on cells. Shen Liang Chen initiated and organized this study and wrote the manuscript.

**ACKNOWLEDGEMENTS**

We thank Dr Marten P. Smidt (Department of Pharmacology and Anatomy, University Medical Center Utrecht) for providing plasmids; Dr Chien Chia Wang and Dr Ching Hui Yeh (Department of Life Sciences, National Central University) for help with footprinting assay.

**FINANCING**

This work was supported by the National Science Council of Taiwan, ROC [NSC-96-2311-B-008-006-MY3 and NSC-99-2314-B-008-001-MY3 (to S.L.C.J.)]. W.C.H. is currently a Ph.D. student supported by funding from the National Health Research Institute in Taiwan.

**REFERENCES**

1. Accili, D. and Arden, K. C. (2004) FoxOs at the crossroads of cellular metabolism, differentiation, and transformation. Cell 117, 421–426
2. Tran, H., Brunet, A., Griffith, E. C. and Greenberg, M. E. (2003) The many forks in FOXO’s road. Sci. STKE 2003, RE5
3. Zhao, H. H., Herrera, R. E., Coronado-Heinsohn, E., Yang, M. C., Ludes-Meyers, J. H., Seybold-Tilson, K. J., Nawaz, Z., Yee, D., Barr, F. G., Diab, S. G. et al. (2003) Forkhead homologue in rhabdomyosarcoma functions as a bifunctional nuclear receptor-interacting protein with both coactivator and corepressor functions. J. Biol. Chem. 278, 27907–27912
4. Barthel, A., Schmoll, D. and Untermann, T. G. (2005) FoxO proteins in insulin action and metabolism. Trends Endocrinol. Metab. 16, 183–189
5. Nakamura, N., Ramaswamy, S., Vazquez, F., Signoretto, S., Loda, M. and Sellers, W. R. (2000) Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN. Mol. Cell Biol. 20, 8969–8982
6. Kortylewski, M., Feld, F., Kruger, K. D., Bahrenberg, G., Roth, R. A., Joost, H. G., Heinrich, P. C., Behrmann, I. and Barthel, A. (2003) Akt modulates STAT3-mediated gene expression through a FKHR (FOXO1α)-dependent mechanism. J. Biol. Chem. 278, 5242–5249
7. Burgering, B. M. and Kops, G. J. (2002) Cell cycle and death control: long live Forkheads. Trends Biochem. Sci. 27, 352–360
8. Bois, P. R. and Grosveld, G. C. (2003) FKHR (FOXO1α) is required for myotube fusion of primary mouse myoblasts. EMBO J. 22, 1147–1157
9. Hribal, M. L., Nakae, J., Kitamura, T., Shutter, J. R. and Accili, D. (2003) Regulation of insulin-like growth factor-dependent myoblast differentiation by Foxo forkhead transcription factors. J. Cell Biol. 162, 535–541
10. Sandri, M., Sandri, C., Gilbert, A., Skurc, C., Calabria, E., Picard, A., Walsh, K., Schiaffino, S., Lecker, S. H. and Goldberg, A. L. (2004) Foxo transcription factors induce the atrophy-related ubiquitin ligase atroglin-1 and cause skeletal muscle atrophy. Cell 117, 399–412
11. Stitt, T. N., Drujan, D., Clarke, B. A., Panaro, F., Timofeyeva, Y., Kline, W. O., Gonzalez, M., Yancopoulos, G. D. and Glass, D. J. (2004) The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol. Cell. 14, 395–403
12. Kamei, Y., Miura, S., Suzuki, M., Kai, Y., Mizukami, J., Taniguchi, T., Mochida, K., Hata, T., Matsuda, J., Abuhatami, H., Ushinou, I. and Ezaki, O. (2004) Skeletal muscle FOXO1 (FKHR) transgenic mice have less skeletal muscle mass, down-regulated Type I (slow twitch/red muscle) fiber genes, and impaired glycemic control. J. Biol. Chem. 279, 41114–41123
13. Hishiya, A., Iemura, S., Natsume, T., Takayama, S., Ikeda, K. and Watanabe, K. (2006) A novel ubiquitin-binding protein ZNF216 functioning in muscle atrophy. EMBO J. 25, 554–564
14. Jacobs, F. M., van der Heide, L. B., Wijchers, P. J., Burbach, J. P., Hoekman, M. F. and Smidt, M. P. (2003) FoxO6, a novel member of the FoxO class of transcription factors with distinct shuttling dynamics. J. Biol. Chem. 278, 35959–35967
15. Hoekman, M. F., Jacobs, F. M., Smidt, M. P. and Burbach, J. P. (2006) Spatial and temporal expression of FoxO1 transcription factors in the developing and adult murine brain. Gene Exp. Patterns 6, 134–140
16. van der Heide, L. B., Jacobs, F. M., Burbach, J. P., Hoekman, M. F. and Smidt, M. P. (2005) FoxO6 transcriptional activity is regulated by Thr26 and Ser184, independent of nucleo-cytoplasmic shuttling. Biochem. J. 391, 623–629
17. Daitoku, H., Yamagata, K., Matsuzaki, H., Hatta, M. and Fukamizu, A. (2003) Regulation of PGC-1 promoter activity by protein kinase B and the forkhead transcription factor FKHR. Diabetes 52, 642–649
18. Wu, Z., Puigserver, P., Andersson, U., Zhang, C., Adelmant, G., Moootha, V., Troy, A., Cinti, S., Lowell, B., Scarulla, R. C. and Spiegelman, B. M. (1999) Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell 98, 115–124
19. Yoon, J. C., Puigserver, P., Chen, G., Donovan, J., Wu, Z., Rhee, J., Adelmant, G., Stafford, J., Kahn, C. R., Granner, D. K. et al. (2001) Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. Nature 413, 131–138
20. Lin, J., Wu, H., Tarr, P. T., Zhang, C. Y., Wu, Z., Boss, O., Michael, L. F., Puigserver, P., Isotani, E., Olson, E. N. et al. (2002) Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres. Nature 418, 797–801
21. Czubryt, M. P., McAnally, J., Fishman, G. I. and Olson, E. N. (2003) Regulation of peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC-1 alpha) and mitochondrial function by MEF2 and HDAC5. Proc. Natl Acad. Sci. U.S.A. 100, 1711–1716
22 Hsiao, S. P., Huang, K. M., Chang, H. Y. and Chen, S. L. (2009) P/CAF rescues the Bhlhe40-mediated repression of MyoD transcriptional activity. Biochem. J. 422, 343–352
23 Lang, K. C., Lin, I. H., Teng, H. F., Huang, Y. C., Li, C. L., Tang, K. T. and Chen, S. L. (2009) Simultaneous overexpression of Oct4 and Nanog abrogates terminal myogenesis. Am. J. Physiol. Cell Physiol. 297, C43–C54
24 Teng, H. F., Kuo, Y. L., Loo, M. R., Li, C. L., Chu, T. W., Suo, H., Liu, H. S., Lin, K. H. and Chen, S. L. (2010) Valproic acid enhances Oct4 promoter activity in myogenic cells. J. Cell Biochem. 110, 995–1004
25 Hsiao, S. P. and Chen, S. L. Myogenic regulatory factors regulate M-cadherin expression by targeting its proximal promoter elements. Biochem. J. 428, 223–233
26 Akimoto, T., Pohnert, S. C., Li, P., Zhang, M., Gumbs, C., Rosenberg, R. B., Williams, R. S. and Yan, Z. (2005) Exercise stimulates Pgc-1alpha transcription in skeletal muscle through activation of the p38 MAPK pathway. J. Biol. Chem. 280, 19587–19593
27 Hsiao, S. P. and Chen, S. L. (2010) Simultaneous overexpression of Oct4 and Nanog abrogates terminal myogenesis. Am. J. Physiol. Cell Physiol. 297, 5148–5155
28 Chang, J. H., Lin, K. H., Shih, C. H., Chang, Y. J., Chi, H. C. and Chen, S. L. (2006) Myogenic basic helix-loop-helix proteins regulate the expression of peroxisomal proliferator activated receptor-gamma coactivator-1alpha. Endocrinology 147, 3093–3106
29 Gundersen, K. (2011) Excitation-transcription coupling in skeletal muscle: the molecular pathways of exercise. Biol. Rev. Camb. Phil. Soc. 86, 564–600
30 Brault, J. J., Jespersen, J. G. and Goldberg, A. L. (2010) Peroxisome proliferator-activated receptor gamma coactivator 1 alpha or 1 beta overexpression inhibits muscle protein degradation, induction of ubiquitin ligases, and disuse atrophy. J. Biol. Chem. 285, 19460–19471
31 Sandri, M., Lin, J., Handschin, C., Yang, W., Arany, Z. P., Lecker, S. H., Goldberg, A. L. and Spiegelman, B. M. (2006) PGC-1alpha protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription. Proc. Natl Acad. Sci. U.S.A. 103, 16260–16265
32 Frühbeck, G. and Martinez, J. A. (2001) Fast and slow PGC-1 mRNA up-regulation in brown adipose tissue of Wistar rats by a beta(3)-adrenergic agonist and lack of effect of leptin. Mol. Cell Endocrinol. 176, 85–90
33 Feingold, K., Kim, M. S., Shigenaga, J., Moser, A. and Grunfeld, C. (2004) Altered expression of nuclear hormone receptors and coactivators in mouse heart during the acute-phase response. Am. J. Physiol. Endocrinol. Metab. 286, E201–E207
34 Weitzel, J. M., Radtke, C. and Seitz, H. J. (2001) Two thyroid hormone-mediated gene expression patterns in vivo identified by cDNA expression arrays in rat. Nucleic Acids Res. 29, 5148–5155
35 Chin, S. P. and Chen, S. L. (2006) Myogenic regulatory factors regulate the expression of peroxisomal proliferator activated receptor-gamma coactivator-1alpha. Endocrinology 147, 3093–3106
36 Gundersen, K. (2011) Excitation-transcription coupling in skeletal muscle: the molecular pathways of exercise. Biol. Rev. Camb. Phil. Soc. 86, 564–600
37 Brault, J. J., Jespersen, J. G. and Goldberg, A. L. (2010) Peroxisome proliferator-activated receptor gamma coactivator 1 alpha or 1 beta overexpression inhibits muscle protein degradation, induction of ubiquitin ligases, and disuse atrophy. J. Biol. Chem. 285, 19460–19471
38 Sandri, M., Lin, J., Handschin, C., Yang, W., Arany, Z. P., Lecker, S. H., Goldberg, A. L. and Spiegelman, B. M. (2006) PGC-1alpha protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription. Proc. Natl Acad. Sci. U.S.A. 103, 16260–16265
39 Crunkhorn, S., Dearie, F., Mantzoros, C., Gami, H., da Silva, W. S., Espinoza, D., Fauchette, R., Barry, K., Bianco, A. C. and Patti, M. E. (2007) Peroxisome proliferator activator receptor gamma coactivator-1 expression is reduced in obesity: potential pathogenic role of saturated fatty acids and p38 mitogen-activated protein kinase activation. J. Biol. Chem. 282, 15439–15450
40 Mootha, V. K., Lindgren, C. M., Eriksson, K. F., Subramanian, A., Sihag, S., Lehr, J., Puigserver, P., Carlsson, E., Ridderstrale, M., Laurila, E. et al. (2003) PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 34, 267–273
41 Michael, L. F., Wu, Z., Cheatham, R. B., Puigserver, P., Adelmant, G., Lehman, J. J., Kelly, D. P. and Spiegelman, B. M. (2001) Restoration of insulin-sensitive glucose transporter (GLUT4) gene expression in muscle cells by the transcriptional coactivator PGC-1. Proc. Natl Acad. Sci. U.S.A. 98, 3820–3825
42 Pfaff, L. J., Knochenhauer, E. S., Vidal-Puig, A., Chandel, N. S., Standifer, J. P., Manke, K. L., Krebs, G. E., Kliewer, S. A. and Puigserver, P. (2002) Suppression of reactive oxygen species and neurodegeneration by the PGC-1 coactivator. Cell 110, 397–408
43 Qin, W., Haroutunian, V., Katsel, P., Cardozo, C. P., Ho, L., Buxbaum, J. D. and Pasinetti, G. M. (2009) PGC-1alpha expression decreases in the Alzheimer disease brain as a function of dementia. Arch. Neurol. 66, 352–361
44 Cui, L., Jeong, H., Borovecki, F., Parkhurst, C. N., Tanese, N. and Krainc, D. (2006) Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 127, 59–69
SUPPLEMENTARY DATA

FoxO6 and PGC-1α form a regulatory loop in myogenic cells

Shih Ying CHUNG*, Wei Chieh HUANG*, Ching Wen SU*, Kuan Wei LEE*, Hsiang Cheng CHI*, Cheng Tao LIN*, Szu-Tah CHEN†, Kai Min HUANG*, Mu Shiun TSAI‡, Hui Peng YU* and Shen Liang CHEN*1

*Department of Life Sciences, National Central University, Jhongli 32001, Taiwan, †Division of Endocrinology and Metabolism, Chang Gung Memorial Hospital, Kweishan 33333, Taoyuan, Taiwan, and ‡Department of Pathology and Medical laboratory, Taiwan Landseed Hospital, Pingjen 32449, Taoyuan, Taiwan

Figure S1 Purified recombinant FoxO6 (amino acid 229–492)-His protein

Various amounts of E. coli expressed recombinant protein was purified with nickel-NTA beads and run on 10% SDS/PAGE gels. Protein on the gel was viewed by Coomassie blue staining. Numbers to the left represent molecular weight in kilodalton (kDa).

1 To whom correspondence should be addressed (email slchen@cc.ncu.edu.tw).

© 2013 The Author(s) This is an Open Access article distributed under the terms of the Creative Commons Attribution Licence (CC-BY) (http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.
### Figure S2  Alignment of the mouse FoxO family mRNAs

The sequence of the mouse FoxO family mRNAs was aligned with Vector NTI software and the lease conserved region among FoxO families is shown here.
Figure S3  FoxO6 antibody recognizes FoxO6-EGFP in HEK-293 cells
HEK-293 cells were transfected with vector expressing FoxO6-EGFP and the expression of FoxO6-EGFP was recognized by immunofluorescence using FoxO6 antibody and viewed with Texas red-conjugated secondary antibody (B). The signals of EGFP (A) and DAPI (4',6-diamidino-2-phenylindole) (C) show significant overlapping with that of FoxO6 (D).

Received 18 March 2013/30 April 2013; accepted 2 May 2013
Published as Immediate Publication 3 May 2013, doi 10.1042/BSR20130031